Sale Of Ranbaxy Feeds Idea Japan Firms Not Good At Foreign Deals
This article was originally published in PharmAsia News
Daiichi Sankyo's bailout from its $4.7 billion purchase of Ranbaxy Laboratories six years ago has served to support a perception of Japan companies being weak in making deals outside of their own country.
You may also be interested in...
Novartis seems to have accepted the fact that the indication granted for Piqray in the EU means there is little scope for the advanced breast cancer drug to be used in markets such as the UK.
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
Latest EU company news: Sanofi grows OTC portfolio in France and Italy with ColdZyme; Germany's WindStar Medical gets UK owners; and France's Ipsen continues to fell effects of COVID-19 on sales.